ABSTRACT
Fluorescence imaging modalities are now beginning to find their niche in disease diagnosis owing to their supreme specificity and sensitivity. One of the emerging trends in understanding various disease pathologies is to view them as metabolic disorders: They either begin as metabolic malfunctions at their early stages (e.g., altered glucose metabolism in tumors or in diabetes) or end up as metabolic dysfunctions (e.g., altered free radical/redox metabolism in age-dependent neurodegeneration).
